{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:39Z","timestamp":1740144159161,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40272-021-00445-3","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T04:02:52Z","timestamp":1617854572000},"page":"299-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of the Implementation of a Vancomycin Protocol on Trough Serum Vancomycin Concentrations in a Pediatric Intensive Care Unit"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5780-4531","authenticated-orcid":false,"given":"Ra\u00edssa Queiroz","family":"Rezende","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00edcero Arm\u00eddio Gomes","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Pires","family":"Ricachinevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Paulo","family":"de Lucena Capelari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"445_CR1","unstructured":"Brunton L, Chabner B, Knollmann B. As bases farmacol\u00f3gicas da terap\u00eautica de Goodman & Gilman. In: 14th ed. Porto Alegre: AMGH; 2012."},{"issue":"11","key":"445_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036.","journal-title":"Am J Health Syst Pharm."},{"key":"445_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:3.","journal-title":"Clin Infect Dis."},{"key":"445_CR4","doi-asserted-by":"crossref","unstructured":"Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J [Internet]. 2013;32(10):1077\u20139. http:\/\/content.wkhealth.com\/linkback\/openurl?sid=WKPTLP:landingpage&an=00006454-201310000-00011.","DOI":"10.1097\/INF.0b013e318299f75c"},{"issue":"1","key":"445_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Heal Pharm. 2009;66(1):82\u201398.","journal-title":"Am J Heal Pharm."},{"key":"445_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1542\/peds.2016-2423","volume":"139","author":"M Miloslavsky","year":"2017","unstructured":"Miloslavsky M, Galler MF, Moawad I, Actis J, Cummings BM, El Saleeby CM. The impact of pediatric-specific vancomycin dosing guidelines: a quality improvement initiative. Pediatrics. 2017;139:6.","journal-title":"Pediatrics"},{"issue":"6","key":"445_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1542\/hpeds.2014-0019","volume":"4","author":"LM Geerlof","year":"2014","unstructured":"Geerlof LM, Boucher J. Evaluation of vancomycin dosing and corresponding drug concentrations in pediatric patients. Hosp Pediatr. 2014;4(6):342\u20137. https:\/\/doi.org\/10.1542\/hpeds.2014-0019.","journal-title":"Hosp Pediatr"},{"issue":"10","key":"445_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.ki.5002231","volume":"71","author":"A Akcan-Arikan","year":"2007","unstructured":"Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71(10):1028\u201335. https:\/\/doi.org\/10.1038\/sj.ki.5002231.","journal-title":"Kidney Int."},{"issue":"1","key":"445_CR9","first-page":"341","volume":"15","author":"P Arfa","year":"2016","unstructured":"Arfa P, Karimi A, Tabatabaei SR, Fahimzad A, Armin S, Sistanizad M. A prospective study to assess vancomycin serum concentrations in pediatric patients with current dosing guidelines. Iran J Pharm Res. 2016;15(1):341\u20136.","journal-title":"Iran J Pharm Res."},{"issue":"5","key":"445_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1542\/hpeds.2014-0081","volume":"5","author":"SH Durham","year":"2015","unstructured":"Durham SH, Simmons ML, Mulherin DW, Foland JA. An evaluation of vancomycin dosing for complicated infections in pediatric patients. Hosp Pediatr. 2015;5(5):276\u201381.","journal-title":"Hosp Pediatr."},{"issue":"12","key":"445_CR11","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/phar.1331","volume":"33","author":"T Madigan","year":"2013","unstructured":"Madigan T, Sieve RM, Graner KK, Banerjee R. The effect of age and weight on vancomycin serum trough concentrations in pediatric patients. Pharmacotherapy. 2013;33(12):1264\u201372.","journal-title":"Pharmacotherapy"},{"key":"445_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jmii.2015.08.027","volume":"2015","author":"D Hwang","year":"2015","unstructured":"Hwang D, Chiu NC, Chang L, Peng CC, Huang DTN, Huang FY, et al. Vancomycin dosing and target attainment in children. J Microbiol Immunol Infect [Internet]. 2015;2015:6\u201311. https:\/\/doi.org\/10.1016\/j.jmii.2015.08.027.","journal-title":"J Microbiol Immunol Infect [Internet]."},{"issue":"1","key":"445_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12887-019-1602-8","volume":"19","author":"TM Maloni","year":"2019","unstructured":"Maloni TM, Belucci TR, Malagutti SR, Furtado GHC. Describing vancomycin serum levels in pediatric intensive care unit (ICU) patients: are expected goals being met. BMC Pediatr. 2019;19(1):240.","journal-title":"BMC Pediatr."},{"issue":"12","key":"445_CR14","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/phar.2191","volume":"38","author":"RB Turner","year":"2018","unstructured":"Turner RB, Kojiro K, Shephard EA, Won R, Chang E, Chan D, et al. Review and validation of bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients. Pharmacotherapy. 2018;38(12):1174\u201383.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"445_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40272-020-00400-8","volume":"22","author":"SJF Hartman","year":"2020","unstructured":"Hartman SJF, Orri\u00ebns LB, Zwaag SM, Poel T, de Hoop M, de Wildt SN. External validation of model-based dosing guidelines for vancomycin, gentamicin, and tobramycin in critically ill neonates and children: a pragmatic two-center study. Pediatr Drugs [Internet]. 2020;22(4):433\u201344. https:\/\/doi.org\/10.1007\/s40272-020-00400-8.","journal-title":"Pediatr Drugs [Internet]."},{"issue":"4","key":"445_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40272-020-00402-6","volume":"22","author":"RB Flint","year":"2020","unstructured":"Flint RB, Allegaert K. Target drug exposure attainment in children: how to get from better to best. Pediatr Drugs [Internet]. 2020;22(4):445\u20137. https:\/\/doi.org\/10.1007\/s40272-020-00402-6.","journal-title":"Pediatr Drugs [Internet]."},{"issue":"2","key":"445_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s11096-012-9614-6","volume":"34","author":"M Swartling","year":"2012","unstructured":"Swartling M, Gupta R, Dudas V, Guglielmo BJ. Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring. Int J Clin Pharm. 2012;34(2):282\u20135.","journal-title":"Int J Clin Pharm."},{"issue":"2","key":"445_CR18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ Van Hal","year":"2013","unstructured":"Van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734\u201344.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"445_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/phar.1259","volume":"33","author":"BR Totapally","year":"2013","unstructured":"Totapally BR, Machado J, Lee H, Paredes A, Raszynski A. Acute kidney injury during vancomycin therapy in critically ill children. Pharmacotherapy. 2013;33(6):598\u2013602.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"445_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/jpids\/pit076","volume":"3","author":"CA Knoderer","year":"2014","unstructured":"Knoderer CA, Nichols KR, Lyon KC, Veverka MM, Wilson AC. Are elevated vancomycin serum trough concentrations achievedwithin the first 7 days of therapy associated with acute kidney injury in children? J Pediatric Infect Dis Soc. 2014;3(2):127\u201331.","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"3","key":"445_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","volume":"158","author":"S McKamy","year":"2011","unstructured":"McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158(3):422\u20136.","journal-title":"J Pediatr."},{"issue":"4","key":"445_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/phar.1227","volume":"33","author":"JJ Cies","year":"2013","unstructured":"Cies JJ, Shankar V. Nephrotoxicity in patients with vancomycin trough concentrations of 15\u201320 \u03bcg\/ml in a pediatric Intensive Care Unit. Pharmacotherapy. 2013;33(4):392\u2013400.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"445_CR23","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/INF.0000000000002391","volume":"38","author":"HS dos Feiten","year":"2019","unstructured":"dos Feiten HS, Okumura LM, Martinbiancho JK, Andreolio C, da Rocha TS, Antonacci Carvalho PR, et al. Vancomycin-associated nephrotoxicity and risk factors in critically ill children without preexisting renal injury. Pediatr Infect Dis J. 2019;38(9):934\u20138.","journal-title":"Pediatr Infect Dis J."},{"issue":"2","key":"445_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1590\/S1413-86702009000200004","volume":"13","author":"AC Gales","year":"2009","unstructured":"Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY program (2005\u20132008). Braz J Infect Dis. 2009;13(2):90\u20138.","journal-title":"Braz J Infect Dis."},{"issue":"4","key":"445_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.bjid.2015.04.009","volume":"19","author":"ACO Silveira","year":"2015","unstructured":"Silveira ACO, Cunha GR, Caier\u00e3o J, de Cordova CM, d\u2019Azevedo PA. MRSA from Santa Catarina State, Southern Brazil: Intriguing epidemiological differences compared to other Brazilian regions. Braz J Infect Dis. 2015;19(4):384\u20139.","journal-title":"Braz J Infect Dis."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00445-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-021-00445-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00445-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T16:29:27Z","timestamp":1620923367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-021-00445-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1007\/s40272-021-00445-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"assertion":[{"value":"19 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ra\u00edssa Queiroz Rezende, C\u00edcero Arm\u00eddio Gomes Dias, Claudia Pires Ricachinevsky, and Jo\u00e3o Paulo de Lucena Capelari have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This study was approved by the Ethics and Research Committee of Hospital da Crian\u00e7a Santo Ant\u00f4nio under No. 2971369.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}